Malignant Retroperitoneal Neoplasm — Trials

Malignant Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 41
Recruiting: 23
Ph III recruiting: 1
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (17)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02637531	A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549	unknown	Phase 1	219	Infinity Pharmaceuticals, Inc.INDUSTRY	1	Apr 4, 2022	clinicaltrials
NCT02587169	Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27)	unknown	Phase 1 / Phase 2	40	Broto, Javier Martín, M.D.INDIV	1	Oct 27, 2015